Clinical Trial Update: Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada

View source ↗

Summary

This clinical trial update reports on evaluating how well physicians understand safety and safe-use information for aflibercept (Eylea) in Canada.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Central Retinal Vein Occlusion
• Diabetic Macular Edema

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Bayer | Conditions: Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO) | Status: COMPLETED